Xintela AB (publ) (STO:XINT)

Market Cap	143.83M -53.2%
Revenue (ttm)	3.03M -38.5%
Net Income	-47.72M
EPS	-0.07
Shares Out	861.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	279,426
Open	0.1525
Previous Close	0.1575
Day's Range	0.1525 - 0.1670
52-Week Range	0.1500 - 0.5340
Beta	1.97
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About Xintela AB

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XINT

Financial Performance

In 2025, Xintela AB's revenue was 2.28 million, a decrease of -45.86% compared to the previous year's 4.22 million. Losses were -48.56 million, 23.9% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 22, 2026

Data Sources Report a data error